ADC Therapeutics SA (ADCT) stock
ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.34−0.07 (-4.96%)
Close on Nov 13, 2026Market cap $171.08MP/E –Yield –
ADC Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
ADC Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $70.17M, down 37.9% year over year. For fiscal 2025 it was $104.01M, down 5.1% from the year before. The highest annual figure on record is $186.46M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.01M | -5.1% |
| FY2024 | Dec 31, 2024 | $109.63M | -13.8% |
| FY2023 | Dec 31, 2023 | $127.13M | -31.8% |
| FY2022 | Dec 31, 2022 | $186.46M | +18.0% |
| FY2021 | Dec 31, 2021 | $158.00M | +11.2% |
| FY2020 | Dec 31, 2020 | $142.03M | +32.1% |
| FY2019 | Dec 31, 2019 | $107.54M | -9.1% |
| FY2018 | Dec 31, 2018 | $118.31M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $14.74M | -45.0% |
| Q2 FY2026 | Jun 30, 2026 | $17.37M | -42.3% |
| Q1 FY2026 | Mar 31, 2026 | $19.88M | -31.3% |
| Q4 FY2025 | Dec 31, 2025 | $18.18M | -32.9% |
| Q3 FY2025 | Sep 30, 2025 | $26.80M | -17.5% |
| Q2 FY2025 | Jun 30, 2025 | $30.09M | +23.9% |
| Q1 FY2025 | Mar 31, 2025 | $28.93M | +12.4% |
| Q4 FY2024 | Dec 31, 2024 | $27.10M | -10.6% |
| Q3 FY2024 | Sep 30, 2024 | $32.50M | +20.0% |
| Q2 FY2024 | Jun 30, 2024 | $24.30M | -22.5% |
| Q1 FY2024 | Mar 31, 2024 | $25.74M | -32.9% |
| Q4 FY2023 | Dec 31, 2023 | $30.33M | -35.9% |
| Q3 FY2023 | Sep 30, 2023 | $27.08M | -35.0% |
| Q2 FY2023 | Jun 30, 2023 | $31.34M | -35.4% |
| Q1 FY2023 | Mar 31, 2023 | $38.38M | -21.6% |
| Q4 FY2022 | Dec 31, 2022 | $47.29M | +11.3% |
| Q3 FY2022 | Sep 30, 2022 | $41.68M | +13.2% |
| Q2 FY2022 | Jun 30, 2022 | $48.54M | +22.8% |
| Q1 FY2022 | Mar 31, 2022 | $48.95M | +25.0% |
| Q4 FY2021 | Dec 31, 2021 | $42.49M | -12.5% |
| Q3 FY2021 | Sep 30, 2021 | $36.81M | +14.5% |
| Q2 FY2021 | Jun 30, 2021 | $39.53M | +52.3% |
| Q1 FY2021 | Mar 31, 2021 | $39.17M | +10.7% |
| Q4 FY2020 | Dec 31, 2020 | $48.55M | – |
| Q3 FY2020 | Sep 30, 2020 | $32.16M | – |
| Q2 FY2020 | Jun 30, 2020 | $25.95M | – |
| Q1 FY2020 | Mar 31, 2020 | $35.38M | – |
See a number that looks wrong?